Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.

Freedman MS, Hughes B, Mikol DD, Bennett R, Cuffel B, Divan V, LaVallee N, Al-Sabbagh A.

Eur Neurol. 2008;60(1):1-11. doi: 10.1159/000127972. Epub 2008 Apr 25. Review.

2.

Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Khan O, Zabad R, Caon C, Zvartau-Hind M, Tselis A, Lisak R.

CNS Drugs. 2002;16(8):563-78. Review.

PMID:
12096936
3.

A composite score to predict short-term disease activity in patients with relapsing-remitting MS.

Sormani MP, Rovaris M, Comi G, Filippi M.

Neurology. 2007 Sep 18;69(12):1230-5. Erratum in: Neurology. 2008 Mar 18;70(12):982.

PMID:
17875911
4.

Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.

Etemadifar M, Janghorbani M, Shaygannejad V.

Acta Neurol Scand. 2006 May;113(5):283-7.

PMID:
16629762
5.
7.

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.

Neurology. 2007 Oct 9;69(15):1498-507. Epub 2007 Aug 15.

PMID:
17699802
8.

Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet].

Smith B, Carson S, Fu R, McDonagh M, Dana T, Chan BKS, Thakurta S, Gibler A.

Portland (OR): Oregon Health & Science University; 2010 Aug.

9.

Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.

Zhao Y, Traboulsee A, Petkau AJ, Li D.

Neurology. 2008 Mar 25;70(13 Pt 2):1092-7. Epub 2007 Nov 14.

PMID:
18003938
10.

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.

Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.

Curr Med Res Opin. 2014 Apr;30(4):613-27. doi: 10.1185/03007995.2013.863755. Epub 2013 Nov 26. Review.

PMID:
24195574
11.

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.

Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K; PRIVIG Study Group; UBC MS/MRI Research Group.

Neurology. 2008 Jul 22;71(4):265-71. doi: 10.1212/01.wnl.0000318281.98220.6f.

PMID:
18645164
12.

Comparative studies of glatiramer acetate and interferon beta.

Goodin D.

Int MS J. 2008 Jun;15(2):39-41.

PMID:
18782497
13.

[Long-term effects of glatiramer acetate in multiple sclerosis].

Brochet B.

Rev Neurol (Paris). 2008 Nov;164(11):917-26. doi: 10.1016/j.neurol.2008.02.045. Epub 2008 May 16. French.

PMID:
18790510
14.

A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.

Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, Mprotsis T, Grigoriadis N, Zintzaras E.

J Clin Pharm Ther. 2013 Dec;38(6):433-9. doi: 10.1111/jcpt.12090. Epub 2013 Aug 20. Review.

PMID:
23957759
15.

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K.

Appl Health Econ Health Policy. 2009;7(2):91-108. doi: 10.2165/11314900-000000000-00000.

PMID:
19731967
16.

Interferon-beta 1b in the treatment of multiple sclerosis.

Río J, Montalban X.

Expert Opin Pharmacother. 2005 Dec;6(16):2877-86. Review.

PMID:
16318438
17.

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.

Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E.

Mult Scler. 2009 Jan;15(1):50-8. doi: 10.1177/1352458508096687. Epub 2008 Oct 15.

PMID:
18922831
18.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
19.

Current disease-modifying treatment of multiple sclerosis.

Derwenskus J.

Mt Sinai J Med. 2011 Mar-Apr;78(2):161-75. doi: 10.1002/msj.20239. Review.

PMID:
21425262
20.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.

PMID:
19308305
Items per page

Supplemental Content

Write to the Help Desk